The Roche group is to acquire Ireland-based Inflazome Ltd and its portfolio of compounds for the treatment of a range of inflammatory diseases. The small molecule drugs inhibit the protein NLRP3 which is expressed in macrophages and is a component of the inflammasome. Activation of the NLRP3 inflammasome is implicated in many diseases caused by chronic, uncontrolled inflammation.
